866823-73-6

Basic information

• Product Name: Biphenylindanone A
• Synonyms: Biphenylindanone A;3'-[[(2-Cyclopentyl-2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-yl)oxy]methyl]-[1,1'-biphenyl]-4-carboxylicacid;BINA;3'-[[(2-Cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy]methyl]biphenyl-4-carboxylic acid;MRLSD 230;[1,1'-Biphenyl]-4-carboxylic acid, 3'-[[(2-cyclopentyl-2,3-dihydro-6,7-diMethyl-1-oxo-1H-inden-5-yl)oxy]Methyl]-;BINA, >=98%
• CAS NO: 866823-73-6
• Molecular Formula: C30H30O4
• Molecular Weight: 454.5568
• EINECS: -0
• Mol File: 866823-73-6.mol

Chemical Properties

• Melting Point: 238-241℃
• Appearance: white to tan/
• Density: 1.220
• Storage Temp.: Desiccate at RT
• Solubility: DMSO: ≥18mg/mL
• CAS DataBase Reference: Biphenylindanone A(CAS DataBase Reference)
• NIST Chemistry Reference: Biphenylindanone A(866823-73-6)
• EPA Substance Registry System: Biphenylindanone A(866823-73-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 866823-73-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Biphenylindanone A is used as a research tool for elucidating the role of mGluR2 in diverse processes such as psychosis, schizophrenia, and drug addiction. Its selectivity and brain penetrance make it a valuable compound for investigating the therapeutic potential of mGluR2 modulation in these conditions.
Used in Drug Development:
Biphenylindanone A is used as a lead compound in the development of new drugs targeting mGluR2 for the treatment of neurological and psychiatric disorders. Its potent stimulation of human and rat mGluR2 receptors, with EC50 values of 33.2 and 96 nM respectively, highlights its potential as a starting point for designing more effective and selective mGluR2 modulators.
Used in Neurotransmission Studies:
Biphenylindanone A is used as a probe to study the modulation of neurotransmitter release by mGluR2, providing insights into the underlying mechanisms of glutamate and GABA signaling in the central nervous system. This can contribute to a better understanding of synaptic function and the development of targeted therapies for various neurological conditions.

Upstream product

• 866823-97-4 2-cyclopentyl-5-{[3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzyl]oxy}-6,7-dimethylindan-1-one 
• 906483-43-0 ethyl 3'-(((2-cyclopentyl-6.7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy)methyl)biphenyl-4-carboxylate 
• 591-17-3 meta-bromotoluene 
• 1122-99-2 2-cyclopentylacetyl chloride 
• 41715-84-8 2-cyclopentyl-5-hydroxy-6,7-dimethyl-indan-1-one 
• 41715-82-6 1-(4-methoxy-2,3-dimethylphenyl)-2-cyclopentyl-2-propenone 
• 41715-83-7 2-cyclopentyl-5-methoxy-6,7-dimethylindan-1-one 
• 1123-00-8 2-cyclopentylacetic acid 
• 134694-64-7 ethyl 3'-bromomethylbiphenyl-4-carboxylate 
• 373623-33-7 m-tolylzinc(II) bromide 
• 223799-25-5 2-(3-(bromomethyl)phenyl)-5,5-dimethyl-1,3,2-dioxa borinane 
• 134694-63-6 ethyl 3'-methyl-[1,1'-biphenyl]-4-carboxylate 
• 41715-81-5 2'-cyclopentyl-2,3-dimethyl-4-methoxyacetophenone 

Relevant articles and documents

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice

Previous studies indicate that agonists of the group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, may provide a novel approach for the treatment of anxiety disorders and schizophrenia. However, the relative contributions of the mGluR2

INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutama

Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor

We have identified and synthesized a series of biphenyl-carboxylic acid indanones as allosteric potentiators of the metabotropic glutamate receptor 2. Structure-activity relationship studies directed toward improving the potency and the brain to plasma ra